Prestige Consumer Healthcare ( (PBH) ) has issued an announcement.
Prestige Consumer Healthcare Inc. surpassed expectations in Q2 of fiscal 2025 with revenue reaching $283.8 million and a diluted EPS of $1.09, attributed to strong international growth and effective capital strategies. Despite challenges with Clear Eyes supply, the company saw a 13% increase in cash flow and reduced debt by $75 million. Looking ahead, Prestige reaffirms its fiscal 2025 outlook, projecting continued revenue growth and profitability driven by its diversified brand portfolio.
For detailed information about PBH stock, go to TipRanks’ Stock Analysis page.
